Tumor News and Research

RSS

Henry Ford physicians use AngioVac device to remove tumor in kidney cancer patient

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal.

13 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

Oral pathogen protects different tumor cells from being killed by immune cells

Bacteria that are commonly found in the mouth are often abundant in patients with colon cancer, but the potential role these microbes play in tumor development has not been clear. A study published by Cell Press February 18th in the journal Immunity reveals that the oral pathogen Fusobacterium nucleatum protects a variety of tumor cells from being killed by immune cells.

12 Feb 2015

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models.

12 Feb 2015

Common protein may play strategic role in tumor growth

A common, yet previously undistinguished protein, which is elevated in many late-stage cancers, may play a strategic role in tumor growth through a non-conventional pathway, researchers at the Indiana University School of Medicine report in the Feb. 10 issue of the Proceedings of the National Academy of Sciences.

12 Feb 2015

SRI Biosciences awarded contract to develop novel polymers to neutralize chemical, biological threats

SRI Biosciences, a division of SRI International, has been awarded a $10 million contract under a DARPA program to reimagine how proteins are constructed and to develop novel medicines and diagnostics as countermeasures to chemical and biological threats.

12 Feb 2015

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.

12 Feb 2015

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

11 Feb 2015

Research findings could lead to new standard of care for soft tissue sarcomas

Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.

11 Feb 2015

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy.

10 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

University of Chicago Medicine researchers have built a model system that uses multiple cell types from patients to rapidly test compounds that could block the early steps in ovarian cancer metastasis. Their three-dimensional cell-culture system, adapted for high-throughput screening, has enabled them to identify small molecules that can inhibit adhesion and invasion, preventing ovarian cancers from spreading to nearby tissues.

10 Feb 2015

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth.

10 Feb 2015

Roche announces acquisition of Signature Diagnostics

Roche announced today the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are constructed from multicenter prospective clinical studies.

From Roche Sequencing and Life Science 10 Feb 2015

Scientists find that collagen 'cross-links' can determine tumor's ability to grow and spread

When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological matrix from which the tumor can thrive and spread.

10 Feb 2015

Drugs designed to target NHE9 protein could help fight glioblastoma

Applying lessons learned from autism to brain cancer, researchers at The Johns Hopkins University have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease.

10 Feb 2015

Discovery leads to new understanding of cancer metastasis

In a breakthrough in the understanding of how cancer spreads, researchers at the University of Virginia School of Medicine have identified a substance secreted by lung cancer cells that enables them to metastasize, beginning their deadly march to other sites in the body.

10 Feb 2015

Tumor News and Research

Henry Ford physicians use AngioVac device to remove tumor in kidney cancer patient

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

Oral pathogen protects different tumor cells from being killed by immune cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Common protein may play strategic role in tumor growth

SRI Biosciences awarded contract to develop novel polymers to neutralize chemical, biological threats

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

UT Southwestern gets NCI grant to establish Heavy Ion Radiation Therapy Research Center in US

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

UT Southwestern leads researchers to establish National Center for Heavy Ion Radiation Therapy

Research findings could lead to new standard of care for soft tissue sarcomas

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Study describes novel screening system that has potential to uncover effective ovarian cancer drugs

Drug similar to Gleevec may help tame some brain cancers

Roche announces acquisition of Signature Diagnostics

Scientists find that collagen 'cross-links' can determine tumor's ability to grow and spread

Drugs designed to target NHE9 protein could help fight glioblastoma

Discovery leads to new understanding of cancer metastasis

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News